BGPT: Paper Review: Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1

Fuel Your Discoveries

Quick Explanation Copied

Key takeaways

DC-2 (compound 42) reports nanomolar DCN1 potency (FP: Ki 20.83 nM context; HTRF: Ki 13.66 ± 1.03 nM) and selective weaker binding to DCN3/4 (Ki 591.72 nM and 807.01 nM) plus reduced potency to DCN5 (Ki 2.14 μM, different unit)
The study argues DC-2 engages DCN1 in vitro and in cells (thermal shift, CETSA) and functionally suppresses CUL3 neddylation while increasing NRF2/HO-1/NQO1
Major scientific gaps include no in vivo efficacy/toxicity, incomplete off-target profiling, and uncertainty from docking-based mechanistic claims not replaced by direct structure determination

Long Explanation

Paper review (science-first, skeptical, evidence-based)

Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1–UBE2M Interaction

Citation:

What the authors claim (explicit):

DC-2 is identified after SAR from a DC-1 series, with reported nanomolar inhibition of DCN1–UBE2M binding in biochemical assays.
DC-2 is said to specifically inhibit the DCN1–UBE2M interaction, engaging DCN1 in cells (CETSA) and reducing CUL3 neddylation, accumulating NRF2 and increasing NRF2 downstream proteins HO-1 and NQO1.

1) Visualizing the core biochemical signal

DC-2 binding/selectivity across human DCN1–DCN5 (reported Ki)

Evidence consistency check (skeptical):

The paper reports DCN5 Ki in μM while other isoforms are in nM .
Converting DCN5 to nM allows visualization, but the key interpretation remains: DC-2 is strongest for DCN1/2 and weaker for DCN3/4/5.

2) Mechanism diagram (known vs inferred vs uncertain)

What is known vs inferred (from the provided text):

Known/assayed: biochemical competitive binding disruption using FP and HTRF, plus protein thermal shift (in vitro) and CETSA in cells, and CUL3 neddylation / NRF2 pathway markers by Western blot after DC-2 treatment.
Inferred mechanism: docking interactions and residue-level importance (Phe164/Tyr181, etc.) are consistent with the biochemical/cellular data, but docking alone is not direct physical evidence; the paper uses site-specific mutations to strengthen this link.
Uncertain/under-specified: the provided text does not include broad off-target profiling; cellular phenotypes (proliferation/apoptosis) might involve downstream network effects common to neddylation pathway perturbation.

3) Potency landscape: from DC-1 to DC-2

The paper’s abstract reports a move from ~1.2 μM (DC-1) to ~15 nM (DC-2) . This is a substantial potency improvement (order-of-magnitude), but the paper excerpt does not show the full IC50 distribution or assay curves for DC-1 across all contexts.

4) SAR logic (what seems mechanistically “hot”)

Mechanistic SAR signals described in the text:

R1/aromatic substitution pattern strongly impacts activity (loss with coumarin substitution in 7–9; improvement with aromatic substitutions and electron-withdrawing groups; position effects such as para Br vs para Cl reported as better).
R2 heterocycle/heteroatom identity is critical: replacing sulfur with nitrogen (compound 19) yields complete loss, while thiazolethiol at R2 leads to highest potency (compound 34 series).
R3 terminal alkyne is evaluated: altering propargyl to ethene/ethyl abolishes activity, and converting to triazole via click also causes large loss, interpreted as steric/hydrophobic interaction geometry requirements.

5) Critique: strengths, then limitations

Strengths (evidence density around target engagement)

Orthogonal biochemical assays (FP and HTRF) are used for competitive binding at the protein interaction level, reducing reliance on a single assay format.
Thermal shift + CETSA supports cellular engagement rather than only biochemical reactivity.
Mutagenesis aligns with docking predictions at residues implicated in the complex (Phe164/Tyr181 effects are highlighted as crucial).

Limitations / red flags (what could mislead)

No in vivo pharmacology/toxicology in the provided content: strong for target mechanism and cell phenotypes, weaker for therapeutic feasibility.
Off-target and pathway-network breadth: CUL3 neddylation suppression and NRF2 activation are measured, but the excerpt does not show proteome-wide changes or direct measurement of other potential neddylation substrates beyond selected cullins.
Docking-based mechanistic claims remain probabilistic: without co-crystal/EM or direct structural determination of DC-2 in DCN1, docking and hydrogen bond distances are supportive but not definitive.
Lead-optimisation within one chemotype: the SAR is extensive for this scaffold, but generalization to other DCN1–UBE2M chemotypes (or addressing resistance mechanisms) is not established in the provided excerpt.

6) Reproducibility checklist (what a replication should include)

Component	Included?	Key details present in text?
Chemistry synthesis & purity	Yes	General synthesis route + HPLC purity & HRMS reported; full experimental details are extensive but not fully contained in the snippet
FP/HTRF competitive binding	Yes	Assay buffers, plate formats, tracer/protein labeling, and Ki calculation equation are described
Thermal shift + CETSA	Yes	Temperature ranges and treatment times/doses are described for CETSA and in vitro thermal shift
Specificity controls	Partial	Uses DC-2N and negative/positive comparators (e.g., MLN4924) and DCN1 siRNA; broad proteomic off-target coverage not described in snippet

Replication risk note: because Ki units differ across isoforms (nM vs μM), replication should preserve reported units and ensure consistent transformations.

7) Key biological interpretation (careful)

The paper’s most defensible chain is: DC-2 inhibits DCN1–UBE2M binding in biochemical assays, engages DCN1 (thermal shifts), and reduces CUL3 neddylation with concomitant activation/accumulation of NRF2 pathway markers in cells. However, the leap from marker changes to “safe/narrower than global neddylation inhibition” is not fully demonstrated in the provided excerpt; “toxicity” and “therapeutic window” require in vivo pharmacology and broader safety profiling.

Explore more on BGPT

Author reviews (BGPT)

Feedback:

Updated: April 02, 2026